DK1446010T3 - Stabiliseret azithromycin-sammensætning - Google Patents
Stabiliseret azithromycin-sammensætningInfo
- Publication number
- DK1446010T3 DK1446010T3 DK02801784T DK02801784T DK1446010T3 DK 1446010 T3 DK1446010 T3 DK 1446010T3 DK 02801784 T DK02801784 T DK 02801784T DK 02801784 T DK02801784 T DK 02801784T DK 1446010 T3 DK1446010 T3 DK 1446010T3
- Authority
- DK
- Denmark
- Prior art keywords
- azithromycin
- stabilized
- compositions
- stabilized azithromycin
- azithromycin composition
- Prior art date
Links
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title abstract 7
- 229960004099 azithromycin Drugs 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 6
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000000087 stabilizing effect Effects 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000000975 co-precipitation Methods 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000003801 milling Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33634601P | 2001-10-18 | 2001-10-18 | |
| US33193101P | 2001-11-21 | 2001-11-21 | |
| US34129501P | 2001-12-17 | 2001-12-17 | |
| PCT/US2002/033339 WO2003032922A2 (en) | 2001-10-18 | 2002-10-18 | Stabilized azithromycin compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1446010T3 true DK1446010T3 (da) | 2009-06-22 |
Family
ID=27406829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02801784T DK1446010T3 (da) | 2001-10-18 | 2002-10-18 | Stabiliseret azithromycin-sammensætning |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6764997B2 (es) |
| EP (1) | EP1446010B1 (es) |
| AT (1) | ATE428403T1 (es) |
| AU (1) | AU2002335087A1 (es) |
| CA (1) | CA2463619C (es) |
| DE (1) | DE60232005D1 (es) |
| DK (1) | DK1446010T3 (es) |
| ES (1) | ES2324527T3 (es) |
| HK (1) | HK1067278A1 (es) |
| HU (1) | HUP0402291A2 (es) |
| IL (1) | IL161398A0 (es) |
| PT (1) | PT1446010E (es) |
| WO (1) | WO2003032922A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200300575A (et) | 2001-05-22 | 2004-04-15 | Pfizer Products Inc. | Asitromütsiini kristalsed vormid |
| US6861413B2 (en) | 2001-05-22 | 2005-03-01 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| US20080149521A9 (en) * | 2001-10-18 | 2008-06-26 | Michael Pesachovich | Methods of stabilizing azithromycin |
| JP2005513099A (ja) * | 2001-12-21 | 2005-05-12 | ファイザー・プロダクツ・インク | アジスロマイシンの直接的に圧縮可能な配合品 |
| RU2283651C2 (ru) * | 2001-12-21 | 2006-09-20 | Пфайзер Продактс Инк. | Способы мокрой грануляции азитромицина |
| EP1478347A1 (en) * | 2002-02-01 | 2004-11-24 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
| EP1594762A1 (en) * | 2003-02-19 | 2005-11-16 | Teva Pharmaceutical Industries Limited | Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container |
| CA2520192A1 (en) * | 2003-03-25 | 2004-10-14 | Teva Pharmaceutical Industries Ltd. | Degradation products of azithromycin, and methods for their identification |
| CA2521462A1 (en) * | 2003-04-17 | 2004-10-28 | Sandoz Ag | Derivatives of azithromycin |
| US20070185194A1 (en) * | 2003-07-01 | 2007-08-09 | Kamal Mehta | Stable oral compositions of azithromycin monohydrate |
| US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| EP1670516A2 (en) * | 2003-09-30 | 2006-06-21 | Solubest Ltd | Water soluble nanoparticles inclusion complexes |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| WO2006067577A2 (en) * | 2004-12-21 | 2006-06-29 | Pfizer Products Inc. | Stable non-dihydrate azithromycin oral suspensions |
| US20060198895A1 (en) * | 2005-03-07 | 2006-09-07 | Kotliar Eleonora M | Azithromycin powder for oral suspension compositions |
| US8906823B2 (en) * | 2007-09-24 | 2014-12-09 | Basf Corporation | Pollutant emission control sorbents and methods of manufacture and use |
| TWI468167B (zh) | 2007-11-16 | 2015-01-11 | 威佛（國際）股份有限公司 | 藥學組成物 |
| US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
| WO2011015219A1 (en) | 2009-08-06 | 2011-02-10 | Shifa Pharmed Industrial Group Co. | Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers |
| RU2512683C2 (ru) * | 2012-06-08 | 2014-04-10 | Общество с ограниченной ответственностью "ВИК-здоровье животных" | Антибактериальная инъекционная фармацевтическая композиция |
| JP7525264B2 (ja) | 2017-04-28 | 2024-07-30 | リベルタス バイオ，インコーポレイティド | アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形 |
| RU2666607C1 (ru) * | 2017-05-03 | 2018-09-11 | Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" | Способ повышения стабильности инъекционной фармацевтической композиции |
| US11654124B2 (en) | 2019-07-29 | 2023-05-23 | Amneal Pharmaceuticals Llc | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
| US10792262B1 (en) * | 2019-07-29 | 2020-10-06 | Saol International Limited | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
| CN111450065B (zh) * | 2020-04-22 | 2022-04-01 | 南京嘉晨医药科技有限公司 | 一种阿奇霉素干混悬剂的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI8110592A8 (en) * | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| WO1996019489A1 (en) * | 1994-12-19 | 1996-06-27 | Russinsky Limited | Compounds |
| US5872104A (en) | 1994-12-27 | 1999-02-16 | Oridigm Corporation | Combinations and methods for reducing antimicrobial resistance |
| CN1205338A (zh) * | 1998-05-08 | 1999-01-20 | 刘万忠 | 阿奇霉素水溶性盐的合成新方法及其在医药上的用途 |
| TW546302B (en) * | 1998-05-08 | 2003-08-11 | Biochemie Sa | Improvements in macrolide production |
| US6239112B1 (en) | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
| CZ20011886A3 (cs) | 1998-11-30 | 2001-10-17 | Teva Pharmaceutical Industries Ltd. | Etanolát azitromycinu, postup přípravy a jeho farmaceutické preparáty |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| IT1313610B1 (it) * | 1999-08-09 | 2002-09-09 | S I F I Societa Ind Farmaceuti | Processo per la preparazione di formulazioni acquose per uso oftalmico |
-
2002
- 2002-10-18 HU HU0402291A patent/HUP0402291A2/hu unknown
- 2002-10-18 AU AU2002335087A patent/AU2002335087A1/en not_active Abandoned
- 2002-10-18 WO PCT/US2002/033339 patent/WO2003032922A2/en not_active Application Discontinuation
- 2002-10-18 CA CA002463619A patent/CA2463619C/en not_active Expired - Fee Related
- 2002-10-18 ES ES02801784T patent/ES2324527T3/es not_active Expired - Lifetime
- 2002-10-18 EP EP02801784A patent/EP1446010B1/en not_active Expired - Lifetime
- 2002-10-18 US US10/274,097 patent/US6764997B2/en not_active Expired - Fee Related
- 2002-10-18 IL IL16139802A patent/IL161398A0/xx unknown
- 2002-10-18 DE DE60232005T patent/DE60232005D1/de not_active Expired - Fee Related
- 2002-10-18 DK DK02801784T patent/DK1446010T3/da active
- 2002-10-18 AT AT02801784T patent/ATE428403T1/de not_active IP Right Cessation
- 2002-10-18 PT PT02801784T patent/PT1446010E/pt unknown
-
2004
- 2004-04-13 US US10/822,773 patent/US20040192622A1/en not_active Abandoned
- 2004-09-07 US US10/936,075 patent/US20050106239A1/en not_active Abandoned
-
2005
- 2005-02-02 HK HK05100860.2A patent/HK1067278A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1067278A1 (en) | 2005-04-08 |
| AU2002335087A1 (en) | 2003-04-28 |
| CA2463619A1 (en) | 2003-04-24 |
| CA2463619C (en) | 2008-05-06 |
| US20030176369A1 (en) | 2003-09-18 |
| ES2324527T3 (es) | 2009-08-10 |
| PT1446010E (pt) | 2009-06-08 |
| US20040192622A1 (en) | 2004-09-30 |
| IL161398A0 (en) | 2004-09-27 |
| WO2003032922A2 (en) | 2003-04-24 |
| DE60232005D1 (de) | 2009-05-28 |
| US20050106239A1 (en) | 2005-05-19 |
| US6764997B2 (en) | 2004-07-20 |
| EP1446010A4 (en) | 2007-06-13 |
| EP1446010B1 (en) | 2009-04-15 |
| ATE428403T1 (de) | 2009-05-15 |
| EP1446010A2 (en) | 2004-08-18 |
| WO2003032922A3 (en) | 2003-10-16 |
| HUP0402291A2 (hu) | 2005-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1067278A1 (en) | Stabilized azithromycin compositions | |
| PT1117440E (pt) | Composicoes farmaceuticas que contem paclitaxel | |
| MXPA05001061A (es) | Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol. | |
| ATE269079T1 (de) | Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans | |
| HUP0402497A3 (en) | Pharmaceutical compositions containing two activ ingredients and their uses | |
| EA200301275A1 (ru) | Капсулы для ингаляции | |
| DE69716435D1 (de) | Xanthangummi enthaltende saure reinigungsmittel | |
| TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
| DE69923471D1 (de) | Injizierbare propofol-formulierungen | |
| CY1105009T1 (el) | Συνθεση καχαλαλιδης f | |
| ES2130575T3 (es) | Composiciones inmunogenicas mejoradas contra la gastrina 17 humana. | |
| IS8334A (is) | Æxilseyðandi samsetningar sem samanstanda af defíbrótíði stöku eða blönduðu með öðrum æxliseyðandi miðlum | |
| ES2180319T3 (es) | Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos. | |
| CO5580729A2 (es) | Composiciones nutricionales que comprenden cistationina | |
| TW200517117A (en) | Stabilized compositions containing an oxygen-labile active agent | |
| EP1136080A3 (en) | Use of o-vanillin and o-vanillin/trolox combinations | |
| EP1541134A3 (en) | Stabilized azithromycin compositions | |
| ATE364619T1 (de) | Tibolonformulierungen | |
| ATE545434T1 (de) | Stabilisierte zusammensetzungen | |
| MY136633A (en) | Stabilized brivudine topical formulations | |
| IL157849A0 (en) | Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives | |
| MXPA03010821A (es) | Composiciones de aroma y fragancias. | |
| ATE208627T1 (de) | Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen | |
| AU2001287673A1 (en) | Novel trioxepan compounds |